11/20/2026 | Press release | Distributed by Public on 11/20/2026 20:26
Abby, Caleb and Liam celebrate the FDA approval of adrabetadex with Dr. Natasha Shur and the Children's National care team who have supported them through years of treatment.
Abby and her parents with Drs. Shur and Wells, marking a milestone years in the making after nearly a decade in the adrabetadex trial.
Caleb and his dad with Drs. Shur and Wells during one of the infusions he has received every two weeks for years at Children's National.
Liam and his dad celebrate his 200th adrabetadex infusion with Drs. Shur and Wells, just days after the drug's FDA approval.
Children and families living with Niemann-Pick disease type C (NPC), a rare and devastating neurodegenerative disorder sometimes called "childhood Alzheimer's," now have a new FDA-approved treatment option: adrabetadex. Children's National helped study the drug for nearly a decade as one of only 13 clinical trial sites in the United States.
Children's National is the only pediatric hospital in the region to offer this drug, which was studied at 30 sites around the world.
"Today's approval is a milestone for the children and families who have trusted us for years, and it shows what can happen when families, clinicians and researchers work together," said Natasha Shur, MD, division chief of Genetics and Metabolism at Children's National and principal investigator. "The biggest miracle is watching these kids grow and thrive, joke, be present and improve."
The patient benefit
NPC is a progressive disease that affects the brain and nervous system. Until recently, families had very few options. Adrabetadex now joins two other FDA-approved NPC treatments.
Abby, Caleb and Liam are three children with NPC, ages 11 to 13, who have taken part in the trial at Children's National for several years, coming to the hospital every two weeks to receive infusions of the drug. Their families, active in the NPC community, first came to Children's National after receiving care at other hospitals, including compassionate use treatment.
Children's National leads the way
Dr. Shur has worked in the NPC community for 15 years. In this trial, she was joined by Laura Tochen, MD, Julie Rhee, NP, and Peter Shibuya, NP, who were instrumental to the work at Children's National. Behind the research, the work of Mirian Naybor, clinical research coordinator, and Julianna Lintner, clinical research compliance specialist, both at Children's National, was essential to keeping the study moving. People on both the clinical and translational side worked together as a multidisciplinary team to help these patients maintain local access to this pivotal trial and the treatment.
What's next
Access to this treatment will be available to newly diagnosed patients with infantile NPC, both at Children's National and across the United States, alongside several other newly approved treatments. With approval in place, Children's National will continue to offer adrabetadex, and patients now in the trial will transition to the clinically standard treatment. The approval culminates nearly two decades of investigational work in which Children's National played a central role. It would not have been possible without the persistent support of this dedicated community, their steadfast adherence to treatment and the many sacrifices they made along the way.